Myriad Genetics, Inc. (NASDAQ:MYGN) VP Richard M. Marsh sold 13,759 shares of the business’s stock in a transaction on Friday, January 12th. The stock was sold at an average price of $36.25, for a total transaction of $498,763.75. Following the completion of the sale, the vice president now directly owns 136,385 shares in the company, valued at approximately $4,943,956.25. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Shares of Myriad Genetics, Inc. (MYGN) opened at $35.79 on Wednesday. The company has a current ratio of 2.34, a quick ratio of 2.06 and a debt-to-equity ratio of 0.09. The company has a market cap of $2,480.00, a price-to-earnings ratio of 24.18, a price-to-earnings-growth ratio of 2.29 and a beta of 0.24. Myriad Genetics, Inc. has a 1 year low of $15.15 and a 1 year high of $37.30.

Myriad Genetics (NASDAQ:MYGN) last issued its quarterly earnings results on Tuesday, November 7th. The company reported $0.26 EPS for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.05. The business had revenue of $190.20 million for the quarter, compared to analysts’ expectations of $183.52 million. Myriad Genetics had a net margin of 13.28% and a return on equity of 9.54%. The business’s quarterly revenue was up 7.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.23 earnings per share. equities research analysts expect that Myriad Genetics, Inc. will post 1.05 EPS for the current fiscal year.

Institutional investors and hedge funds have recently modified their holdings of the business. GHP Investment Advisors Inc. boosted its position in Myriad Genetics by 11.1% during the third quarter. GHP Investment Advisors Inc. now owns 48,710 shares of the company’s stock valued at $1,762,000 after acquiring an additional 4,853 shares during the last quarter. Vanguard Group Inc. boosted its position in Myriad Genetics by 0.9% during the second quarter. Vanguard Group Inc. now owns 6,307,738 shares of the company’s stock valued at $162,992,000 after acquiring an additional 56,708 shares during the last quarter. PDT Partners LLC bought a new stake in Myriad Genetics during the second quarter valued at $8,481,000. Shell Asset Management Co. raised its holdings in shares of Myriad Genetics by 34.3% during the third quarter. Shell Asset Management Co. now owns 54,867 shares of the company’s stock valued at $2,116,000 after purchasing an additional 14,021 shares during the period. Finally, Prudential Financial Inc. raised its holdings in shares of Myriad Genetics by 3.9% during the third quarter. Prudential Financial Inc. now owns 131,073 shares of the company’s stock valued at $4,742,000 after purchasing an additional 4,900 shares during the period.

Several analysts recently weighed in on the stock. Zacks Investment Research raised shares of Myriad Genetics from a “hold” rating to a “strong-buy” rating and set a $42.00 price objective on the stock in a research note on Tuesday, October 17th. Morgan Stanley reissued an “underweight” rating and issued a $24.00 price objective (up previously from $17.00) on shares of Myriad Genetics in a research note on Friday, October 6th. Stephens reissued an “overweight” rating and issued a $40.00 price objective (up previously from $36.00) on shares of Myriad Genetics in a research note on Friday, September 22nd. ValuEngine cut shares of Myriad Genetics from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Finally, Leerink Swann reissued a “market perform” rating and issued a $31.00 price objective on shares of Myriad Genetics in a research note on Monday, October 2nd. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and three have issued a buy rating to the stock. Myriad Genetics has a consensus rating of “Hold” and a consensus target price of $30.09.

COPYRIGHT VIOLATION WARNING: This report was originally published by Watch List News and is the property of of Watch List News. If you are accessing this report on another website, it was copied illegally and republished in violation of U.S. and international copyright and trademark law. The original version of this report can be accessed at https://www.watchlistnews.com/myriad-genetics-inc-mygn-vp-richard-m-marsh-sells-13759-shares/1810200.html.

About Myriad Genetics

Myriad Genetics, Inc is a molecular diagnostic company. The Company is engaged in the discovery, development and marketing of transformative molecular diagnostic tests. The Company operates through two segments: diagnostics and other. The diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual’s risk for developing disease later in life, identify a patient’s likelihood of responding to drug therapy and guide a patient’s dosing to enable optimal treatment, or assess a patient’s risk of disease progression and disease recurrence.

Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.